NCT07350850 A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL Status RECRUITING Phase PHASE2
NCT06914700 A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators: Status COMPLETED Phase N/A
NCT06554561 A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma Status RECRUITING Phase PHASE1/PHASE2
NCT05896007 Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT Status RECRUITING Phase PHASE2
NCT05167630 Prognosis Factors in Patients With Primary Central Nervous System Lymphoma Status UNKNOWN Phase N/A
NCT05021770 Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma Status UNKNOWN Phase PHASE1/PHASE2
NCT04514393 Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma Status UNKNOWN Phase PHASE2
NCT04481815 Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Status RECRUITING Phase PHASE2
NCT04438044 A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL Status UNKNOWN Phase PHASE2